Indian pharmaceutical companies rank top30
Searching the Web
top 30 Indian pharmaceutical companies ranking 2025 2026 by revenue market cap
Reading Web Page
https://www.globaldata.com/companies/top-companies-by-sector…
Searching the Web
top 30 pharmaceutical companies India BSE NSE market cap ranking 2026 complete list
Here is the Top 30 Indian Pharmaceutical Companies ranked by market capitalisation (2025-26 data from BSE/NSE, GlobalData, and Nifty Pharma Index):
Top 30 Indian Pharma Companies by Market Cap (2026)
| Rank | Company | Market Cap (approx.) | HQ | Key Strength |
|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries | ~₹4.43 lakh cr / $44.7B | Mumbai | India's largest pharma; specialty generics, dermatology, oncology; 100+ countries |
| 2 | Divi's Laboratories | ~₹1.82 lakh cr / $21B | Hyderabad | Pure-play API & CRAMS leader; supplies 95+ countries |
| 3 | Torrent Pharmaceuticals | ~₹1.52 lakh cr / $15.1B | Ahmedabad | Chronic branded generics (cardiac, CNS); #1 in Germany & Brazil among Indian cos |
| 4 | Cipla | ~₹1.13 lakh cr / $11.1B | Mumbai | Respiratory, ARV, HIV/oncology access; founded 1935 |
| 5 | Lupin | ~₹1.12 lakh cr / $11.2B | Mumbai | Inhalation, anti-TB APIs, biosimilars; 8th largest in India pharma market |
| 6 | Dr. Reddy's Laboratories | ~₹1.05 lakh cr / $10.5B | Hyderabad | Global generics, biosimilars, vaccines; ROCE ~20% |
| 7 | Mankind Pharma | ~₹85,000-90,000 cr / $12B* | Delhi | Domestic branded formulations; deep Tier 2/3 penetration |
| 8 | Zydus Lifesciences | ~₹98,802 cr / $9.3B | Ahmedabad | Biologics, vaccines, US formulations; semaglutide approvals |
| 9 | Aurobindo Pharma | ~₹69,000 cr / $8.0B | Hyderabad | Generics + API; exports to 150+ countries; oncology & biosimilars pipeline |
| 10 | Alkem Laboratories | ~₹69,000 cr / $6.7B | Mumbai | Anti-infectives, analgesics; strong branded generics |
| 11 | Abbott India | ~₹62,241 cr | Mumbai | MNC subsidiary; women's health, metabolics, diagnostics |
| 12 | Glenmark Pharmaceuticals | ~₹55,105 cr / $6.4B | Mumbai | Dermatology, respiratory, oncology; Ichnos Biosciences spin-off |
| 13 | Biocon | ~₹45,590 cr | Bengaluru | Biologics & biosimilars pioneer; insulin, oncology MAbs |
| 14 | IPCA Laboratories | ~₹33,971 cr | Mumbai | Anti-malarials, cardiovascular, APIs |
| 15 | Piramal Pharma | ~₹25,410 cr | Mumbai | CDMO services, complex injectables, branded generics |
| 16 | J.B. Chemicals & Pharmaceuticals | ~₹22,000-24,000 cr | Mumbai | Cardiac, GI, derma; strong in Russia & South Africa |
| 17 | Natco Pharma | ~₹20,000 cr | Hyderabad | Oncology generics, specialty APIs, US para-IV pipeline |
| 18 | Ajanta Pharma | ~₹18,000-20,000 cr | Mumbai | Branded generics; Africa, Asia, cardio & derma |
| 19 | Sanofi India | ~₹15,000-17,000 cr | Mumbai | MNC subsidiary; diabetes, vaccines, CNS |
| 20 | Pfizer India | ~₹14,000-16,000 cr | Mumbai | MNC subsidiary; hospital injectables, vaccines, oncology |
| 21 | Suven Pharmaceuticals | ~₹13,000-15,000 cr | Hyderabad | Specialty APIs, CRAMS for CNS drugs |
| 22 | Granules India | ~₹10,000-12,000 cr | Hyderabad | Bulk actives, PFIs, finished dosages; paracetamol major |
| 23 | Solara Active Pharma Sciences | ~₹9,000-10,000 cr | Chennai | Standalone API manufacturer |
| 24 | Strides Pharma Science | ~₹8,000-9,000 cr | Bengaluru | Regulated market injectables & softgels |
| 25 | Laurus Labs | ~₹20,000+ cr | Hyderabad | ARV APIs & finished dosages; CDMO oncology |
| 26 | Eris Lifesciences | ~₹8,000-9,000 cr | Ahmedabad | Chronic therapies; diabetes, cardiac, CNS |
| 27 | Sequent Scientific | ~₹5,000-6,000 cr | Mumbai | Animal health / veterinary pharma |
| 28 | Wockhardt | ~₹5,000 cr | Mumbai | Antibiotic R&D (novel antibiotics pipeline), injectables |
| 29 | Cadila Pharmaceuticals (private) | N/A (unlisted) | Ahmedabad | Private; oncology, biologics, veterinary |
| 30 | Venus Remedies / Marksans Pharma | ~₹3,500-4,500 cr | - | Niche formulations, EU/US generic exports |
*Mankind Pharma's GlobalData figure is from Sep 2024 ($12B); more recent BSE data shows₹85,000-90,000 cr. Laurus Labs (₹20,000+ cr) would rank higher than some entries above if using latest data.
Key Highlights
- India is the world's 3rd largest pharma producer by volume and supplies ~20% of global generic medicines.
- Sun Pharma dominates with a ~23% weight in the Nifty Pharma Index and 8.4% domestic prescription share (March 2026).
- FY26 standouts: Sun Pharma revenue ₹58,462 cr (+11.9%); Divi's Labs PAT jumped 65% in Q3 FY26.
- Biosimilars & semaglutide (GLP-1) are the hottest growth areas in 2026 - Zydus, Lupin, Torrent all entered the semaglutide market.
- India pharma market size: ~$68 billion (2025), forecast to reach ~$175 billion by 2034 at ~11% CAGR - per IMARC Group.
This is a shared conversation. Sign in to Orris to start your own chat.